Our tumor-selective technology unleashes the power of immunotherapy

Xilio’s proprietary technology allows us to create novel immunotherapies that preferentially bind their targets in tumors while minimizing activity in healthy non-tumor tissues. To engineer our tumor-selective therapies, we start with a highly potent cytokine or antibody which is then inactivated by fusing it to a “blocking domain”. The blocking domain contains a cleavage site that can be cut by a protein called a protease. The blocking domain inhibits the binding of the molecule to its target(s) thereby inhibiting the function of the molecule until it is cleaved by the proteases which are found predominantly in the tumor microenvironment. This results in a tumor-selective biologic. This approach is intended to bring the benefits of immuno-oncology therapies to patients by minimizing toxicity while enhancing anti-tumor efficacy.

Systemically Active
Immunotherapies

Human body icon outlining an example of the effects of tumor-selective immunotherapies for a person with lung cancer Human body icon outlining an example of the effects of non–tumor selective immunotherapies for a person with lung cancer Human body icon outlining an example of the effects of non–tumor selective immunotherapies for a person with lung cancer Human body icon outlining an example of the effects of non–tumor selective immunotherapies for a person with lung cancer

Lung Cancer Example

With existing therapeutic options, patients receive systemically active immunotherapy in order to treat tumors locally
The simulation of the immune system by currently available immunotherapies is not limited to the tumor, which can lead to severe side effects in organs and tissues
To minimize these systemic side effects, physicians may reduce the dose of the therapy which unfortunately, also reduces its efficacy within the tumor

Xilio Tumor Selective
Immunotherapies

Human body icon outlining an example of the effects of tumor-selective immunotherapies for a person with lung cancer Human body icon outlining an example of the effects of tumor-selective immunotherapies for a person with lung cancer Human body icon outlining an example of the effects of tumor-selective immunotherapies for a person with lung cancer Human body icon outlining an example of the effects of tumor-selective immunotherapies for a person with lung cancer

Lung Cancer Example

Xilio’s technology unleashes the anti-tumor efficacy of immunotherapy predominantly at the tumor.
Xilio’s product candidates are designed to preferentially bind their targets in tumors while minimizing activity in healthy non-tumor tissues.
By utilizing therapies created by Xilio’s technology, a highly efficacious dose of the therapy may be administered with a low risk of side effects, potentially allowing more patients to benefit from immunotherapy treatment vs. non-tumor-selective options.

Xilio product candidates have demonstrated potent, selective anti-tumor activity in preclinical models